MEDICARE REVAMPING REIMBURSEMENT COMMITTEE TO CREATE MORE OPEN PROCESS; COVERAGE FOR NEW TECHNOLOGIES EMERGING AS KEY ISSUE FOR UPCOMING SESSION
This article was originally published in The Gray Sheet
Medicare carriers will be temporarily excluded from the Health Care Financing Administration's Technology Advisory Committee (TAC) while the agency develops a plan to reconstitute the panel to conform with the Federal Advisory Committee Act.
You may also be interested in...
High dose chemotherapy and stem cell transplantation combination treatment for multiple myeloma will be reviewed Sept. 15-16 by the Health Care Financing Administration Medicare Coverage Advisory Committee's drugs, biologics and therapeutics panel, an Aug. 13 Federal Register notice states.
Aker BioMarine seeks supplement firms to use its EPA/DHA innovation bound by lysophosphatidylcholine to enable the fatty acids to pass through the blood-brain and blood-retinal barriers and boost of eye and brain health benefits. It will submit an NDI notificaion in the US during 2022.